FOUNDAYO

all catalysts(0)

nothing on the calendar yet

News(10)

• Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
  After two rejections, Replimune has made it across the regulatory finish line with its advanced melanoma therapy. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, rep…
  biospace · 5d ago
• Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
  Medicare’s new weight loss drug program “risks creating barriers at precisely the moment when confidence in broader GLP‑1 coverage is most needed,” writes Jeffrey Millstein.
  stat · 6d ago
• STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
  Sanofi is experiencing shortages of two medicines used to treat Pompe disease after the FDA warned the company over manufacturing issues
  stat · 7d ago
• Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
  Foundayo clocked $98 million in sales in Q2, the first quarter it was available, compared to Novo’s $355 million for the same sales period.
  biospace · 11d ago
• Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
  A legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicin…
  biospace · 12d ago
• Lilly climbs, Novo falls as obesity drug battle intensifies
  A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.
  biopharma_dive · 12d ago
• Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
  Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the e…
  biospace · 12d ago
• Novo CEO sees innovation as a matter of survival amid pipeline setbacks
  Novo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…
  biospace · 12d ago
• Lilly and Resilience invest $750M in diabetes and obesity drug device supply
  The investment will expand Resilience’s U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.
  biospace · 17d ago
• Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
  Novo Nordisk's IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.
  biospace · 17d ago